Zobrazeno 1 - 10
of 29
pro vyhledávání: '"O. V. Rodnenkov"'
Autor:
E. S. Allakhverdiev, E. A. Rezukhina, O. V. Slatinskaya, O. V. Rodnenkov, Zh. V. Bochkova, N. A. Brazhe, G. V. Maksimov, T. V. Martynyuk
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 4, Pp 56-63 (2023)
Aim: to assess the effectiveness of PAH-specific therapy, including selexipag, based on data from a comprehensive examination and assessment of oxygen transport function in patients with IPAH using Raman spectroscopy.Materials and methods. The study
Externí odkaz:
https://doaj.org/article/204aeae773cc4a9a8ad7a17f5921573f
Autor:
E. S. Allakhverdiev, E. A. Rezukhina, O. V. Slatinskaya, O. V. Rodnenkov, G. V. Maksimov, T. V. Martynyuk
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 3, Pp 44-52 (2023)
In the complex pathogenesis of idiopathic pulmonary arterial hypertension (IPAH), which includes changes in biochemical and biophysical processes in various cell types as the cause of structural and functional impairment, inflammation and thrombosis
Externí odkaz:
https://doaj.org/article/5ca90f3705534f5d81d62c86f266e88e
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 2, Pp 48-55 (2023)
Aim: to evaluate demographic and disease characteristics in pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) patients.Materials and methods: the study enrolls 68 patients with PAH-CTD. These patients were diagnosed
Externí odkaz:
https://doaj.org/article/70165964c31847e78479423586f987b6
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 1, Pp 94-99 (2023)
Aim: to evaluate demographic and disease characteristics in pulmonary arterial hypertension (PAH) patients, for which selexipag is prescribed as PAH-specific treatment.Materials and methods: the study enrolls 73 patients with PAH, where there were 49
Externí odkaz:
https://doaj.org/article/b819853243f040bb8a55ce88f9ab4983
Autor:
M. A. Markov, M. P. Davydova, D. U. Usachev, Vasilii A. Lukshin, T. V. Balakhonova, O. V. Rodnenkov, T. V. Martynyuk
Publikováno v:
Системные гипертензии, Vol 17, Iss 2, Pp 61-64 (2020)
Background. Pulmonary hypertension (PH) is a severe pathology that often leads a patient to death or disability. Recently, the development of PH associated with activation of the sympathetic nervous system (SNS) has been of interest. Some results obt
Externí odkaz:
https://doaj.org/article/53a194c80387459bb86f5c1381899a9e
Autor:
T. V. Martynyuk, A. M. Aleevskaya, O. V. Rodnenkov, A. V. Zorin, A. M. Kasparova, S. N. Nakonechnikov, I. E. Chazova
Publikováno v:
Евразийский Кардиологический Журнал, Vol 0, Iss 2, Pp 54-60 (2020)
The pandemic of a new coronavirus infection – COVID-19 («Coronavirus disease 2019») has changed the routine management of patients with pulmonary arterial hypertension (PAH). Like patients with other chronic cardiovascular diseases, PAH patients
Externí odkaz:
https://doaj.org/article/4a265e37f7b340e79246f068fa31c7e8
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 20, Iss 5 (2021)
We present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology
Externí odkaz:
https://doaj.org/article/867be1d2cb784d6b815586743556e2fc
Autor:
N A Doroshchuk, A Iu Postnov, A D Doroshchuk, Z B Khasanova, N V Konovalova, Iu D Khesuani, M K Osiaeva, O V Rodnenkov, I E Chazova
Publikováno v:
Терапевтический архив, Vol 86, Iss 12, Pp 72-77 (2014)
AIM. To study the impact of simulated climatic conditions of the 2010 summer in Moscow on the telomere repeats of chromosomes in human blood cells. MATERIALS AND METHODS. The climatic conditions of July-August 2010 in Moscow were simulated at the Med
Externí odkaz:
https://doaj.org/article/ebe2a18f79994983bb4efefdbba2ebda
Autor:
I E Chazova, Mikhail V. Arkhipov, Olga D. Ostroumova, A N Rogoza, Tatiana R. Kameneva, Tamila Martynyuk, L. A. Khaisheva, Shurat B. Gorieva, Yury I. Grinshtein, O. V. Rodnenkov, Oxana Rotar, A. S. Galyavich
Publikováno v:
Системные гипертензии, Vol 18, Iss 1, Pp 50-62 (2021)
Aim. To assess the efficacy and safety of Vamloset (amlodipine/valsartan 5/80, 5/160, 10/160 mg) and Co-Vamloset (amlodipine/valsartan/hydrochlorothiazide 10/160/12.5, 10/160/25 mg) in achieving the target levels of blood pressure (BP) in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ded939f077bf26d9b013ee002c424ef
https://syst-hypertension.ru/2075-082X/article/viewFile/65116/47936
https://syst-hypertension.ru/2075-082X/article/viewFile/65116/47936
Autor:
A N Rogoza, Oxana Rotar, Tamila Martynyuk, Shurat B. Gorieva, Tatiana R. Kameneva, Yury I. Grinshtein, Albert S. Galiavich, Mikhail V. Arkhipov, Olga D. Ostroumova, O. V. Rodnenkov, I E Chazova, L. A. Khaisheva
Publikováno v:
Системные гипертензии, Vol 17, Iss 3, Pp 59-70 (2020)
Aim. Assessment of Vamloset® and Co-Vamloset effects on blood pressure target levels and indicators associated with organ protection: albuminuria; elasticity of arteries and central aortic pressure (CAP); endothelial function; tumor necrosis factor-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e0b648560e699afeadff1e80f39e93
https://doi.org/10.26442/2075082x.2020.3.200414
https://doi.org/10.26442/2075082x.2020.3.200414